Diabetes leader DeFronzo receives $250,000 Hamm Prize

February 16, 2017

Ralph DeFronzo, M.D., professor of medicine and chief of diabetes in the Long School of Medicine at UT Health San Antonio, has been selected to receive the 2017 Harold Hamm International Prize for Biomedical Research in Diabetes, which includes $250,000. Dr. DeFronzo is the author of 750 publications and has contributed innovative ideas defining the […]

diabetes in men


Diabetes in Control: Effectiveness of A GLP-1 Receptor Agonist Plus A TZD for Type 2 Diabetes

February 16, 2017

The study was done to examine the efficacy and safety of combination therapy with the GLP-1 receptor agonist exenatide plus the TZD pioglitazone versus basal-bolus insulin in poorly controlled type 2 diabetic patients with very high HbA1c (HbA1c>10%) on metformin plus sulfonylurea and long duration of disease. Read the full story at Diabetes in Control





Health Day News: Adipose Tissue Insulin Resistance Up in Obese-NGT, IGT, T2DM

December 30, 2016

Resistance to the antilipolytic effect of insulin (Adipo-IR) is increased in obese individuals with normal glucose tolerance (NGT), and in those with impaired glucose tolerance (IGT) and type 2 diabetes (T2DM), according to a study published online Jan. 4 in Diabetes. Read the full story at Health Day News